araag2/HINT huggingface dataset:
Clinical trial NCT00430677 (phase 2/phase 3, status: terminated)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: corticosteroids (prednisone or prednisolone), abatacept, abatacept, mycophenolate mofetil (mmf), abatacept
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, COC(=O)\C=C\C(O)=O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Reason stopped: 
    terminated due to failure to meet the primary efficacy endpoint in the short-term period
  
Eligibility criteria:

        Inclusion Criteria:

          -  Systemic Lupus Erythematosus (SLE) as defined by meeting at least 4 of the 11
             classification criteria of the American College of Rheumatology for the classification
             of Systemic Lupus Erythematosus, either sequentially or coincident. The 4 criteria
             need not be present at study entry

          -  Renal biopsy within 12 months prior to screening visit indicating active proliferative
             lupus glomerulonephritis (met ISN/RPS Class III or IV classification criteria [2003],
             excluding Class III [C], IV-S [C] and IV-G [C], or the World Health Organization Class
             III or IV classification criteria [1982], excluding Class IIIc, IVd). If the renal
             biopsy was performed >3 months but ≤12 months prior to screening visit, at least 1 of
             the following 3 serologies (performed locally) must have been abnormal prior to
             screening visit: complement (C3 or C4) level below normal range OR anti-dsDNA >upper
             limit of normal range.

          -  A stable serum creatinine ≤3 mg/dL

        Exclusion Criteria:

          -  Subjects with a rise in serum creatinine of ≥1 mg/dL within 1 month prior to the
             screening visit

          -  Subjects with drug-induced SLE, as opposed to idiopathic SLE

          -  Subjects with severe, unstable and/or progressive Central nervous system (CNS) lupus

          -  Subjects with autoimmune disease other than SLE as their main diagnosis (e.g.;
             Rheumatoid arthritis (RA), Multiple Sclerosis [MS])

          -  Subjects who have received treatment with cyclophosphamide within 3 months of
             randomization (Day 1).

          -  Subjects who have received treatment with rituximab < 6 months prior to the screening
             visit
Clinical trial NCT00096070 (phase 2, status: completed)
Conditions: adenocarcinoma of the pancreas, stage ii pancreatic cancer, stage iii pancreatic cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C25.3, C25.3
Drugs: oxaliplatin, fluorouracil, gemcitabine hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

               -  Unresectable disease, including subtotal resection and gross residual disease

               -  Locally advanced disease

          -  No cystadenocarcinoma of the pancreas

          -  No pancreatic tumors of neuroendocrine origin

          -  No microscopic residual disease as only evidence of pancreatic cancer

          -  All disease must be encompassable within standard radiotherapy fields for pancreatic
             cancer

          -  No distant metastases (liver or lung metastases or peritoneal spread)

               -  No evidence of metastatic disease outside the planned radiotherapy field

          -  Performance status - ECOG 0-1

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN

          -  Creatinine ≤ 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Able to maintain adequate oral nutrition

          -  No significant infection

          -  No significant nausea or vomiting

          -  No other medical condition that would preclude study participation

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer, carcinoma
             in situ of the cervix, or organ-confined prostate cancer (Gleason score < 7)

          -  No known allergy to platinum compounds

          -  No prior biologic therapy

          -  No concurrent biologic therapy

          -  No concurrent immunotherapy

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

          -  No prior radiotherapy that would overlap planned radiotherapy fields

          -  No other concurrent radiotherapy

          -  See Disease Characteristics

          -  At least 21 days since prior laparotomy
Clinical trial NCT00300716 (phase 2/phase 3, status: completed)
Conditions: multiple sclerosis, cognition disorders
ICD codes: G35, C81.18, F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5
Drugs: memantine
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Eligibility criteria:

        Inclusion Criteria:

          1. A diagnosis of multiple sclerosis as defined by the McDonald criteria. Patients with
             relapsing-remitting, secondary progressive, and primary progressive forms of MS are
             eligible.

          2. Age between 18 and 65 years.

          3. Demonstrated cognitive dysfunction at screening defined as a score worse than 1.0
             standard deviations below the mean on the PASAT or the CVLT-II.

        Exclusion Criteria:

          1. A history of major depression, psychosis, or a score > 19 on the Beck's Depression
             Inventory.

          2. Corrected binocular visual acuity worse than 20/50; any impairment of binocular color
             vision.

          3. Patients that do not speak English as a primary language (fluency may impact
             performance).

          4. A clinically significant MS exacerbation within 30 days of the screening

          5. Pregnancy

          6. Renal insufficiency.

          7. History of seizures.

          8. Patients using acetazolamide (Diamox, Ak-sol, Storzolamide), dichlorphenamide
             (Daranide), methazolamide (Neptazane) or topiramate (Topamax), dextromethorphan
             (Robitussin DM and other cold remedies), or amantadine (Symmetrel).

          9. Use of medical marijuana in the prior six months.

         10. History of alcohol abuse or illicit drug use in the prior six months.
Clinical trial NCT01031498 (phase 2, status: completed)
Conditions: acute myelogenous leukemia, chemotherapy-induced nausea and vomiting
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D61.810
Drugs: ondansetron, palonosetron
SMILES: CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2
Eligibility criteria:

        Inclusion Criteria:

          1. Patients > 18 years with acute myelogenous leukemia or high-risk myelodysplastic
             syndrome undergoing chemotherapy with high dose cytarabine (1.5 or 2gm/m^2) containing
             regimens.

          2. Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study, in keeping with the policies of the hospital.

        Exclusion Criteria:

          1. Patients with emesis or grade 2 nausea (oral intake is significantly decreased) or 3
             nausea (no significant intake requiring intravenous fluids)</= 24 hours before
             chemotherapy.

          2. Patients with ongoing emesis due to any organic etiology.

          3. Patients with known hypersensitivity to the study drug or to other selective 5-HT3
             receptor antagonists.
Clinical trial NCT00720434 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: pf-00868554, pf-00868554, pf-00868554, placebo
SMILES: CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1, CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1, CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment naive (no prior treatment with IFN-a +/- RBV regimens.

          -  Subjects who have discontinued IFN-a containing regimens after <2 weeks of therapy due
             to tolerability issues are considered treatment naive.

          -  HCV RNA > 100,000 IU/mL at screening.

          -  Genotype 1.

          -  A diagnosis of chronic HCV infection for at least 6 months.

        Exclusion Criteria:

          -  Evidence of acute or chronic infection with HIV or HBV.

          -  Exposure within the previous three months to an investigational anti-HCV agent.

          -  Evidence of severe or decompensated liver disease.

          -  Subjects with liver disease unrelated to HCV infection.
Clinical trial NCT02275598 (phase 2, status: unknown status)
Conditions: hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: brentuximab vedotin, abvd
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Previously-untreated patients with classical Hodgkin Lymphoma according to the World
             Health Organisation (WHO) classification

          -  Histologically confirmed CD30+ HL

          -  Stage IA, IIA, IIIA

          -  Absence of bulky disease

          -  FDG-PET at baseline

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Life expectancy > 6 months.

          -  Age 18-70 years.

          -  Patients must be available for periodic blood sampling, study-related assessments, and
             management of toxicity at the treating institution.

          -  Females of childbearing potential must have a negative pregnancy test result within
             three days of enrollment. All patients must agree to use effective contraceptive
             methods (one for male and two for female) during the course of the study and for 6
             months following the end of full treatment (Brentuximab vedotin + ABVD +/-
             Radiotherapy).

          -  Written informed consent.

          -  Required baseline laboratory data:

        Absolute neutrophil count ≥ 1000/μl Platelet count ≥ 50.000/ μl Serum bilirubin ≤ 1.5 times
        ULN Serum creatinine ≤ 1.5 times ULN Alanine aminotransferase (ALT) and aspartate
        aminotransferase (AST) ≤ 2.5 times ULN

        Exclusion Criteria:

          -  Peripheral neuropathy > Grade 1

          -  Histologic diagnosis different from Hodgkin Lymphoma

          -  Compressive symptoms

          -  Patients previously treated with any anti-CD30 antibody

          -  Known human immunodeficiency virus (HIV) positive

          -  Known hepatitis B surface antigen-positive, or known or suspected infection active
             hepatitis C

          -  Patients with signs or symptoms of progressive multifocal leukoencephalopathy (PML)

          -  Patients with known cerebral/meningeal disease.
Clinical trial NCT00672646 (phase 2, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: azd1386, naproxen, placebo
SMILES: COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients scheduled for surgical removal of one partial or complete impacted mandibular
             third molar.

          -  Provision of signed informed consent.

        Exclusion Criteria:

          -  History of somatic disease/condition, which may interfere with the objectives for the
             study, as judged by the investigator.

          -  Clinically significant illness or clinically relevant trauma within the 2 weeks prior
             to the administration of the investigational product, as judged by the investigator.

          -  A family history of short QT syndrome (SQTS) or sudden cardiac death (SCD) amongst
             first degree relatives

          -  Patients with a body temperature >37.5°C at Visit 2, before start of surgical
             procedures
Clinical trial NCT00533039 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: varespladib (a-002), placebo
SMILES: CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)C=CC=C2N1CC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women ≥ 18 years of age undergoing elective PCI, with or without stenting

        Exclusion Criteria:

          -  ST elevation MI or any troponin elevation (non-STEMI) within preceding 10days

          -  Elevation of CK-MB or troponin I at baseline

          -  Recent (4 weeks) coronary bypass surgery

          -  NYHA class III-IV heart failure

          -  Left ventricular ejection fraction < 0.30

          -  Severe valvular heart disease

          -  Chronic inflammatory disease (e.g., lupus, rheumatoid arthritis, inflammatory bowel
             disease), or patients receiving steroid drugs

          -  Presence of severe liver disease with cirrhosis

          -  Recent active hepatitis

          -  Active chronic hepatitis

          -  ALT or AST > 3 × upper limit of normal (ULN)

          -  Biliary obstruction with hyperbilirubinemia (total bilirubin > 2 × ULN)

          -  Moderate or severe renal impairment (creatinine > 1.5 × ULN)

          -  Nephrotic syndrome or subjects undergoing dialysis

          -  Uncontrolled diabetes (HbA1c > 11% 1 month prior to screening)

          -  Initiation of statin therapy within 30 days

          -  Inability to provide consent.
Clinical trial NCT01133886 (phase 2, status: unknown status)
Conditions: acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60, C93.11, C93.12, C93.10, D46.9, D46.C, D46.Z
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Written signed informed consent.

          2. ≥18 years of age.

          3. Diagnosed MDS with 5% or more marrow blasts and IPSS risk intermediate 2 or high risk;
             or chronic myelomonocytic leukemia (CMML-2); or AML with 20-30% bone marrow blasts.

          4. Patients who have failed therapy with azacitidine.

          5. Performance status 0-2 (ECOG scale).

          6. Adequate hepatic (bilirubin < 1.5 X ULN or AST< 2.5 X ULN) and renal functions
             (creatinine <1.5 X ULN).

        Exclusion Criteria:

          1. Nursing and pregnant females.

          2. Females of childbearing potential and males not willing to practice an effective
             method of contraception whilst receiving decitabine and for 2 months after the last
             infusion.

          3. Patients with previous malignancy or concurrent malignancy.

          4. Uncontrolled intercurrent illness including, but not limited to, symptomatic
             congestive heart failure and unstable angina pectoris.

          5. Ongoing oral corticosteroids are not permitted. However, use of corticosteroids
             (topical and inhaled) is permitted and prophylactic steroids are allowed for
             transfusion reactions.

          6. Patients who have received any investigational agent within the 30 days preceding the
             first dose of study drug.

          7. Patients who have received prior intensive combination chemotherapy or high-dose
             cytarabine (>/= 1g/m*2 per dose). (Prior biologic therapies, targeted therapies and
             single agent chemotherapy are allowed).

          8. Patients who have an active viral or bacterial infection. Note: No patient is allowed
             to enter the study unless infections have been fully treated and the patient has
             remained afebrile for 7 days without antibiotics.

          9. Patients who have concurrent autoimmune hemolytic anemia or immune thrombocytopenia.

         10. Patients who have previously been treated with decitabine.

         11. Patients who have known positive serology for HIV.

         12. Patients with a condition that may be unable to comply with the treatment and
             monitoring requirements of the study.
Clinical trial NCT00467844 (phase 2, status: completed)
Conditions: cachexia
ICD codes: R64
Drugs: gtx-024, gtx-024, placebo
SMILES: C[C@](O)(COC1=CC=C(C=C1)C#N)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F, C[C@](O)(COC1=CC=C(C=C1)C#N)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        To be eligible for participation in this study, subjects must meet all of the following
        criteria:

          -  have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4
             colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3
             or 4 breast cancer.

          -  be prior to initiation of or between cycles of chemotherapy.

          -  have experienced greater than or equal to 2% weight loss from the highest patient
             reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body
             weight)

             % weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6
             months x 100%

          -  If surgery is part of the cancer treatment, screening for this study should be
             conducted at least 2 weeks (14 days) after surgery.

          -  have a life expectancy of >6 months

          -  FEMALES - be clinically confirmed as postmenopausal

          -  MALES - over 45 years of age

          -  ECOG score ≤1

        Exclusion Criteria:

        Subjects with any of the following will NOT be eligible for enrollment in this study:

          -  history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic
             cirrhosis, or HIV infection

          -  Cardiovascular: No uncontrolled hypertension

          -  Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen),
             anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV

          -  Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents (such
             as DHEA, androstenedione, and other androgenic compounds, including herbals), or
             antiandrogens (Please note that previous therapy with testosterone and
             testosterone-like agents is acceptable with a 30 day wash-out. However, if the
             previous testosterone therapy was a long-term depot, within the past 6 months, the
             site should call the medical monitor for this study to determine appropriate washout
             period.)

          -  Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any
             prescription medication intended to increase appetite or treat unintentional weight
             loss
Clinical trial NCT02694718 (phase 2, status: completed)
Conditions: rectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed locally advanced T3/T4 rectal carcinoma with or without nodal
             involvement requiring surgery of the primary tumor

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  Adequate values of laboratory parameters

        Exclusion Criteria:

          -  Evidence of distant metastases

          -  Previous Chemotherapy or immunotherapy for colorectal cancer

          -  Previous radiotherapy to the pelvis

          -  Pre-existing condition which would deter radiotherapy

          -  Malignancy within last 5 years, except cured basal cell cancer of the skin and in situ
             cancer of the cervix

          -  Clinically significant cardiac disease or myocardial infarction within the last 12
             months

          -  Lack of physical integrity of the upper gastrointestinal tract or those who have
             malabsorption syndrome

          -  Organ allografts

          -  Concomitant treatment with brivudine, lamivudine, ribavirin or any other nucleoside
             analogues

          -  Dihydropyrimidine dehydrogenase (DPD) deficiency

          -  History of uncontrolled seizures, central nervous system disorders, or psychiatric
             disability judged by the investigator to be clinically significant, precluding
             informed consent or interfering with compliance for oral drug intake
Clinical trial NCT01028963 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, pioglitazone, ccx140-b, ccx140-b
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosed type 2 diabetes mellitus

          -  Must have a body mass index ≥25 and <45 kg/m2, but if body mass index is ≥25 and <28
             kg/m2, then waist circumference must be >94 cm for men and >80 cm for women

          -  Must be on a stable dose of metformin for at least 8 weeks prior to randomization

          -  Hemoglobin A1c (HbA1c) of 6.5 to 10.0% inclusive and fasting plasma glucose 135 to 270
             mg/dL inclusive at Screening

        Key Exclusion Criteria:

          -  Type 1 diabetes mellitus or history of diabetic ketoacidosis

          -  Received insulin treatment within 12 weeks of randomization

          -  Received chronic (more than 7 days) systemic glucocorticoid treatment within 12 weeks
             of randomization

          -  Received sulfonylurea, thiazolidinedione, exenatide, or any other glucose lowering
             treatment (other than metformin) within 8 weeks of randomization

          -  Symptomatic congestive heart failure requiring prescription medication, clinically
             evident peripheral edema, poorly-controlled hypertension (systolic blood pressure >160
             or diastolic blood pressure >100), history of unstable angina, myocardial infarction
             or stroke within 6 months of randomization, or chronic renal failure

          -  History or presence of drug-induced myopathy, drug-induced creatine kinase elevation,
             or leukopenia (WBC count <3.5 x 10(9)/L)

          -  History or presence of any form of cancer within the 5 years prior to randomization,
             with the exception of excised basal cell or squamous cell carcinoma of the skin, or
             cervical carcinoma in situ or breast carcinoma in situ that has been excised or
             resected completely and is without evidence of local recurrence or metastasis

          -  Fasting serum triglyceride >400 mg/dL